It doesn’t take a genius to see why PMCB is ready to run up as early as Monday morning!
Time is running out. You have to act fast if you want to profit.
My newest alert is a biotech gem that has just received a 20-year patent for its diabetes treatment and I believe that given the scale of news at the moment, the stock’s unbelievable low price is a major catalyst.
The diabetes treatment market is exploding at the moment. Globally diabetes is wreaking havoc and few companies are able to deliver the kind of treatment that is necessary and at the pace that it is needed.
The company you are about to look at understands this intimately. In the company’s own release it talked about the need for participation in doing its part in “bringing a treatment to tens of millions of these patients.”
PharmaCyte Biotech, Inc. (OTCQB: PMCB)
The diabetes problem is now a global problem and estimates put the cost of treating the disease at close to $1T. This has created a huge growth opportunity for companies that are working to bring much-need treatment to sufferers.
This reality is helping to spur on my newest play, PMCB.
PMCB has just a 20-year patent for “Melligen” cells that are a part of the company’s therapy for Type 1 and insulin-dependent Type 2 diabetes.
The news has sent a flood of eyeballs to the company but I believe the full effect of the development is just about ready to take hold.
My reason for thinking this is simple: diabetes is now dominating the news. Recently there was a massive story in the Montana Standard about a spike in insulin prices. Patients are in crisis so the importance of PMCB’s novel cell-in-a-box technology is bound to take on greater significance.
Obviously I don’t want you to wait until the herd realizes how important PMCB is to the diabetes market. By then you might not be able to make a punt.
You certainly won’t be able to access PMCB’s upside for less than 10 cents… Yes, the play is super accessible right now and it has the right chart formation to match.
RSI levels are very close to support so there is massive upside and bounce potential at current levels.
Recent spikes in daily volatility suggest that the play might be getting ready to turn the corner and RUN.
Don’t let PMCB pick up pace without you. Start your research now.
Here’s a link to the chart: http://stockcharts.com/h-sc/ui?s=PMCB
PMCB’s (PharmaCyte Biotech) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box” This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed.
Global Diabetes Drug Market Will Reach $55.3B Next Year
A new report by visiongain predicts the world market for diabetes medications will reach $55.3B in 2017. The antidiabetic medicines industry generated $35.6B in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Diabetes Treatments: World Drug Market 2013-2023, published in April 2013. Visiongain is a business information provider based in London, UK.
The analysis shows human insulins and analogues dominated the antidiabetics market in 2012. Furthermore, that submarket will maintain dominance in the overall diabetes treatments market to 2023. Also, rapid uptake of dipeptidyl peptidase (DPP)-4 inhibitors will stimulate overall revenue growth, owing to their safety profiles and once-daily dosage regimens. The overall diabetes drugs market will thus achieve strong growth to 2013, especially from 2013 to 2017. Its future is promising, based on existing drugs and agents under development. It has strong, broad-ranging R&D.
Visiongain’s study concludes that an increase in the worldwide incidence of type 1 and type 2 diabetes, coupled with increases in obesity, will stimulate growth of the diabetes drugs market. In addition, the new study predicts the market will increase in competition, as the development of type 1 and type 2 diabetes treatments remains profitable for pharmaceutical companies in the short and long term. Also, with companies entering the market from 2013, visiongain predicts more collaborations and alliances. In addition, the diabetes treatment industry and market will encourage combination therapy, with drugs developed as a monotherapy finding it harder in future to gain market share.
As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection
NEW YORK, NY–(Marketwired – July 19, 2016) – Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of millions of these patients.
PharmaCyte recently learned from the U.S. Patent and Trademark Office (USTPO) that it now has 20 years of patent protection in the United States for the “Melligen” cells that are a part of the company’s therapy for Type 1 and insulin-dependent Type 2 diabetes. The timing is perfect because the same research that laid out the dramatic rise in the numbers of people affected by diabetes, also found that the global cost of diabetes has ballooned to $825-billion per year.
To learn more about PMCB please visit their website: http://pharmacyte.com/
Check out PMCB now.
We have been compensated $30k cash via bank wire by a third party, Ben Loh, LLC, to conduct investor relations advertising and marketing for PMCB. Stellar Media’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.